全文获取类型
收费全文 | 1816篇 |
免费 | 104篇 |
国内免费 | 74篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 105篇 |
妇产科学 | 11篇 |
基础医学 | 117篇 |
口腔科学 | 1篇 |
临床医学 | 182篇 |
内科学 | 270篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
特种医学 | 13篇 |
外科学 | 49篇 |
综合类 | 332篇 |
预防医学 | 424篇 |
药学 | 201篇 |
中国医学 | 247篇 |
肿瘤学 | 31篇 |
出版年
2024年 | 1篇 |
2023年 | 19篇 |
2022年 | 50篇 |
2021年 | 62篇 |
2020年 | 77篇 |
2019年 | 38篇 |
2018年 | 49篇 |
2017年 | 49篇 |
2016年 | 60篇 |
2015年 | 75篇 |
2014年 | 182篇 |
2013年 | 142篇 |
2012年 | 168篇 |
2011年 | 159篇 |
2010年 | 153篇 |
2009年 | 96篇 |
2008年 | 96篇 |
2007年 | 80篇 |
2006年 | 65篇 |
2005年 | 53篇 |
2004年 | 51篇 |
2003年 | 42篇 |
2002年 | 18篇 |
2001年 | 24篇 |
2000年 | 18篇 |
1999年 | 15篇 |
1998年 | 12篇 |
1997年 | 16篇 |
1996年 | 11篇 |
1995年 | 14篇 |
1994年 | 8篇 |
1993年 | 14篇 |
1992年 | 13篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 9篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有1994条查询结果,搜索用时 15 毫秒
1.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
2.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
3.
4.
5.
6.
《Vaccine》2019,37(34):4775-4777
Diarrhea remains one of the top five causes of disease and death among young children in developing nations. Fortunately, scientists are making progress developing vaccines against enterotoxigenic E. coli (ETEC) and Shigella, two of the leading diarrhea pathogens. As vaccine developers start to consider field efficacy trials of these vaccines, they should be aware of the importance of evaluating not only vaccine direct effects on the immunized, but also the herd effects that vaccination can afford to the unimmunized in a community. In a workshop held at the conference titled “Vaccines against Shigella and ETEC (VASE)”, we described to participants what herd effects are and we presented on methods used in cholera and rotavirus studies that could be useful for future ETEC and Shigella vaccine trials conducted in low and middle-income nations. We also presented evidence on the effects of vaccine herd effects for estimates of vaccine cost-effectiveness. 相似文献
7.
目的 基于中医传承辅助平台软件(V2.5)提供的数据分析平台,研究清代方剂专著论述泄泻的用药规律,供现代中医临床辨证用药参考。方法 查阅中华医典(第5版)中的79部清代方剂专著,选择其中10部专门论述“泄泻”的方剂专著,建立数据库,通过中医传承辅助平台软件(V2.5)集成的药物“频次统计”、“规则分析”等功能,对治疗泄泻的用药规律进行分析。结果 本研究共筛选出93首泄泻处方,含药物119味,挖掘出高频(频次 ≥ 5)药物20味,高频(频次 ≥ 13)药物组合12组,演化得到19个核心药物组合和6首新处方。结论 清代方剂专著中治疗泄泻的方剂,多用利水消肿药、补益药,切合本病脾虚湿盛的病机。中医传承辅助平台(V2.5)可实现对于方剂数据的录入、管理、查询和分析,是一个富有价值的辅助中医药研究的工具。 相似文献
8.
《Vaccine》2020,38(47):7440-7444
BackgroundFollowing a recommendation by the World Health Organization, Madagascar introduced rotavirus vaccine in 2014. Though national rotavirus vaccine coverage has remained <80%, rotavirus hospitalizations declined by 78%. Gavi, the Vaccine Alliance, has provided financial support for rotavirus vaccine, however the Malagasy government has increasing responsibility for the financial cost.MethodsIn this evaluation, we describe the direct medical, direct non-medical, and indirect cost of illness due to diarrhea among children <5 years old at a public pediatric referral hospital. A 3-part structured questionnaire was administered during and following the hospitalization and the child’s hospital record was reviewed.ResultsIn total, 96 children were included in this analysis. The median total cost of the illness was $156.00 (IQR: 104.00, 210.86) and the median direct medical cost was $107.22. Service delivery costs represented a median of 44% of the inpatient costs; medications and diagnostic tests represented a median of 28% and 20% of the total costs of the hospitalization, respectively. The median percentage of the total illness costs paid by the household was 67%. Among households with income of <$61/month, the median costs of the illness paid by the household were $78.55, representing a median of 168% of the household’s monthly expenses. Among households earning >$303/month, the median costs paid by the household were $147.30, representing a median of 53% of the household’s monthly expenses. Among all household income levels, caregivers commonly paid these bills from savings, borrowed money, and donations.ConclusionsOur findings will be useful in assessing the cost-effectiveness of rotavirus vaccine by decisionmakers. These results may also help hospital administrators and healthcare providers better understand the financial constraints of families. 相似文献
9.
目的:探究痛泻四神汤对腹泻型肠易激综合征胃肠激素水平的影响。方法:选取2017年2月至2018年6月西安市中医医院收治的腹泻型肠易激综合征患者124例作为研究对象,按照就诊顺序编号随机分为对照组和观察组,每组62例。对照组给予西医常规治疗,观察组在对照组基础上加用痛泻四神汤加减治疗,均治疗2周。观察和比较2组治疗前后淋巴细胞指标CD3^+、CD4^+、CD8^+、CD4^+/CD8^+变化,观察并比较2组治疗前后胃肠激素指标血浆胃动素(MOT)、降钙素相关基因肽(CGRP)、血管活性肠肽(VIP)、生长抑素(SS)、一氧化氮(NO)变化;观察并比较2组治疗前后在γ-干扰素(IFN-γ)、5-羟色胺(5-HT)、神经肽Y(NPY)含量变化;观察并比较2组治疗前后临床症状腹痛、腹胀、肠鸣失气、急躁易怒、神疲乏力、纳呆食少症状评分变化;治疗过程中进行不良反应记录,治疗结束后进行统计。结果:1)2组患者治疗前CD3^+、CD4^+、CD8^+、CD4^+/CD8^+比较,差异无统计学意义(P>0.05),治疗后2组CD3^+、CD4^+、CD4^+/CD8^+较治疗前均显著上升,CD8^+显著下降(均P<0.05);治疗后观察组患者CD3^+、CD4^+、CD4^+/CD8^+显著高于对照组,CD8^+显著低于对照组(P<0.05)。2)2组治疗前MOT、CGRP、VIP、SS、NO比较,差异无统计学意义(P>0.05),治疗后2组MOT、NO较治疗前显著升高,CGRP、VIP、SS显著下降(P<0.05);治疗后观察组CGRP、VIP、SS显著低于对照组,MOT、NO显著高于对照组(P<0.05)。3)2组治疗前IFN-γ、5-HT、NPY比较,差异无统计学意义(P>0.05),治疗后2组IFN-γ、5-HT、NPY较治疗前均显著下降(P<0.05);治疗后观察组IFN-γ、5-HT、NPY显著低于对照组(P<0.05)。4)2组治疗前腹痛、腹胀、肠鸣失气、急躁易怒、神疲乏力、纳呆食少积分比较,差异无统计学意义(P>0.05),治疗后2组以上各症状评分较治疗前显著下降(P<0.05);治疗后观察组以上各积分显著低于对照组(P<0.05)。5)2组口干、头痛、皮疹、胃肠道反应发生率比较,差异无统计学意义(P>0.05)。结论:痛泻四神汤能改善腹泻型肠易激综合征胃肠激素水平,改善临床症状,提高机体免疫力,提高疗效。 相似文献
10.
《中国中医基础医学杂志》2020,(4):542-544
全国名中医、孟河医派传人单兆伟教授擅长胃肠病诊治,临证擅用《金匮要略》温经汤治疗女性肾虚型泄泻。认为温经汤的主要适应证是肝肾虚寒型的女性腹泻和(或)月经不调,肝脾肾三脏虚寒、寒凝而瘀、虚瘀相因、寒热错杂是温经汤证的病机特点,泄下清谷、脉象沉细或细涩、舌质淡黯有齿痕或瘀点是温经汤的主要应用指证。 相似文献